Epinephrine Articles
Struggling La Jolla Pharma saved by merger with Adamis
8 December 2009
Sanofi-Aventis gains US/Canada Rights to novel epinephrine auto-injector from Intelliject for up to $230 million
1 December 2009
UCB and Verus to commercialize Twinject in Europe
28 August 2006
King initiates pivotal Ph III US Vanquix trial
16 January 2006
Merck KGaA's EpiPen gets OK in Japan
11 August 2003
Merck KGaA seeks stand-alone marketing in Japan
17 March 2003
Stock Commentary - New York
18 March 2002
Alpharma posts Q4 2001 net loss
18 March 2002
Matrix files in Europe for IntraDose approval
28 November 2001
Matrix to file IntraDose with EMEA
15 October 2001
Matrix slumps as FDA panel rejects IntraDose product; shares suspended
11 September 2001
IntraDose advisory scheduled for next week
4 September 2001
29% tumor response with Matrix' IntraDose
16 October 2000
Matrix to file NDA for IntraDose
25 May 2000
Trial halted on poor results with FMdC
11 October 1999
IntraDose granted expedited review in USA
26 May 1999
Setback for Senetek's AdrenaJect
21 January 1999
Senetek & ICN Agreement For AdrenaJect (ReliaJect)
29 October 1998
Promising Data With Matrix' IntraDose
18 June 1998
Matrix Terminates US AccuSite Program
17 September 1997
Russian Drug Output Fails To Meet Demand
27 January 1997
FDA Year-End Approvals Round-Up
8 January 1996
Survival Technology's Epi E-Z Pen
4 September 1995
US FDA Cttees View epinephrine, Ephedrine
5 December 1994
BARRE LABS GAINS FDA APPROVAL
17 May 1993
FAST APPROVAL FOR STERLING WINTHROP
22 March 1993
Showing 1-32 of 32 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
